Treatment of H. pylori infection: the reality. by Vakil, N.
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124.
Copyright © 1999. All rights reserved.
Treatment ofH. pylori Infection: The Reality
Nimish Vakil
University ofWisconsin Medical School, Milwaukee Wisconsin
Despite the wide dissemination of information on Helicobacterpylori, there is
still a great deal of variation in how general practitioners treat the infection and
in which circumstances they prescribe eradication therapy for H. pylori.
Specialty societies have developed consensus guidelines that recommend a
strategy to test and treat dyspeptic patients for H. pylori infection although the
data to support these recommendations are weak at the present time. As aresult,
there is still confusion about the indications fortreatment and the treatment reg-
imens that are likely to be effective in routine clinical practice.
INTRODUCTION
There are compelling data to suggest that treatment ofHelicobacterpylori infection
in patients with duodenal ulcer disease is associated with an improvement in health out-
comes and areduction in disease management costs. Despite the data, there is a great deal
of confusion about therapy, and surveys of primary care physicians suggest that signifi-
cant numbers ofpatients receive inadequate therapy. The challenge, therefore, is to trans-
late results obtained in randomized controlled trials (efficacy data) into results obtained in
routine clinical practice (effectiveness data).
PRIMARY CARE PHYSICIANS AND H. PYLORI INFECTION
The attitudes of primary care physicians to the treatment of H. pylori infection have
been examined in several studies. In one study conducted in a family practice in 1995,
Penston and Mistry studied 154 patients treated forH. pylori infection [1]. Eighty percent
were treated for duodenal ulcer and the remainder for non-ulcer dyspepsia or reflux dis-
ease. They found that H. pylori infection was documented in only a third ofpatients prior
to the initiation of therapy. The vast majority of these patients were, therefore, receiving
empirical therapy in the absence ofdocumented infection. Furthermore, when they exam-
ined the regimens being prescribed, they found that 56 different treatment regimens had
been prescribed, and the most frequently prescribed regimen was omeprazole and amox-
icillin, a poor regimen for the eradication ofH. pylori. The management ofpatients with
complicated ulcer disease was particularly poor and did not assure against future hemor-
rhage or perforation. In a more recent study, Breuer et al. reported a survey of486 fami-
ly practitioners who filled out a questionnaire [2]. Eighty-nine percent of them reported
that they treated patients for H. pylori infection at first presentation with ulcer disease.
Sixty-five percent treated all H. pylori-infected patients regardless of the clinical circum-
stances, and 72 percent treated patients with non-ulcer dyspepsia. These data were signif-
icantly different from gastroenterologists, 98 percent ofwhom treated patients with ulcer
disease while only 43 percent treated non-ulcer dyspepsia and 24 percent treated all H.
pylori-positive cases regardless ofclinical circumstances.
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Dyspepsia andpeptic ulcer disease
Dyspepsia is defined as apersistent or recurrent abdominal pain centered in the upper
abdomen. Dyspepsia is a common finding in clinical practice, but symptoms have a poor
predictive value for the underlying diagnosis [3]. Approximately halfofthe patients pre-
senting to primary care doctors with dyspepsia have a functional disorder, and only 15
percent ofthem have peptic ulcer disease. Unfortunately, this is not as well appreciated in
primary care as it should be. In a recent survey ofprimary care physicians, we found that
48 percent ofthem believed that symptoms ofulcer disease were strongly correlated with
the endoscopic diagnosis [4]. A number of studies on H. pylori eradication in non-ulcer
dyspepsia have been published, and all have been criticized for their methodology [5]. At
the present time, it appears that only a minority ofpatients with non-ulcer dyspepsia will
benefit from therapy directed at H. pylori infection.
In 1985, the American College of Physicians published a guideline on dyspepsia
which suggested thatpatients should be given an empirical trial ofH2 receptorantagonists
and undergo further testing only ifsymptoms relapsed or ifthey persisted despite therapy.
[6]. These guidelines have been widely used by managed care organizations to determine
which patients should undergo endoscopy but were never systematically analyzed until
1996. Bytzer et al. [7] randomized patients to treatment with H2 receptor antagonists, as
recommended by the American College of Physicians, or early endoscopy and followed
the patients for a year thereafter. Patients were cared for by primary care physicians who
determined if endoscopy or further interventions should be performed. At the end of one
year, patient satisfaction was poorer, drug costs were higher and the time lost from work
was higher in the group of patients randomized to initial H2 receptor antagonist therapy.
A large percentage of the patients initially randomized to H2 receptor antagonist therapy
eventually had endoscopy for recurrent or unresolved symptoms. This study and the dis-
covery ofH. pylori infection have rendered these guidelines obsolete. It is not surprising,
given the poor results with this guideline that it has had a limited impact on routine clin-
ical practice.
In 1996, the European H. pylori study group issued guidelines on the management of
dyspeptic patients and suggested that patients 45 years or younger should be tested and
treated for H. pylori using a non-invasive test. It was suggested that older patients or
patients with so-called alarm symptoms (bleeding, weight loss, early satiety) should
undergo investigation because of the small but increased risk of missing a gastric malig-
nancy in these subjects [9]. These guidelines are consensus based and cannot claim to
have met the criteria for an evidence-based approach. Economic models suggest that sero-
logic testing and treatment become cost-effective as an initial strategy when as few as 15
percent ofpatients are cured of their symptoms. Preliminary data from our group suggest
that complete cure ofall symptoms that is sustained for one yearmay be possible in a sub-
stantial number ofinfectedpatients, supporting theposition ofthese consensus statements
[10].
H. pylori infection has been associated with gastric cancer in several epidemiological
studies. A recent economic model suggested that it might be cost-effective to test and treat
patients for H. pylori infection to prevent gastric cancer [11]. Preliminary data from
patients with early gastric cancer in Japan suggest that when H. pylori infection is eradi-
cated, there is a significant reduction in the rate of new gastric cancers that develop at
other sites in the stomach [12]. There are no dataupon which aclearrecommendation may
be made at the present time.
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TREATMENT REGIMENS
1. FDA approved regimens
There are three dual drug regimens in the United States, and all have similar eradica-
tion rates:
Omeprazole and clarithromycin. The eradication rate with this regimen was 78 per-
cent in U.S. trials and 82 percent in European trials [13, 14]. Compliance has generally
been good, and the regimen is generally well tolerated. The principal side-effect is taste
perversion due to clarithromycin.
Ranitidine bismuth citrate and clarithromycin. Ranitidine bismuth citrate is a new
compound that is a highly soluble form ofbismuth. An eradication rate of 82 percent was
reported in the United States [4]. Higher eradication rates have been reported in European
studies.
There is only one study thatcompares two dual therapies in arandomized trial. In this
study, eradication rates were lower than in other reports and were significantly better for
the combination of ranitidine bismuth citrate with clarithromycin (73 percent) compared
to omeprazole with clarithromycin (53 percent) [15].
Bismuth-based triple therapy. Bismuth-based triple therapy consists ofa combination
ofbismuth, metronidazole and tetracycline. Amoxicillin has been used instead oftetracy-
cline with poorer results. The three drugs are generally co-prescribed with an anti-secre-
tory drug (H2 receptor antagonist or proton pump inhibitor) in patients with peptic ulcer
disease. With this regimen, 16-18 pills need to be taken every day, which affects compli-
ance. Eradication rates as high as 95 percent have been reported in some studies, but the
overall eradication rate is probably lower in U.S. studies and averages 82 percent.
2. Other regimens: short triple therapies
To decrease cost and enhance compliance, shorter periods oftherapy have been tried
with a variety of agents, administered twice a day. These regimens are generally simpler
to take, and lower doses of some drugs reduce side-effects.
Proton pump inhibitor based triple therapies. Proton pump inhibitors (lansoprazole,
omeprazole) used in combination with two antibiotics are a major advance in the therapy
ofH. pylori infection. Two large European trials have shown ahigh degree ofefficacy [17,
18]. Seven, 10 and 14-day therapy have been reported to yield similar results in European
studies, but in the United States, a decrease in efficacy has been reported with seven-day
therapy, and at the current time, 10-day therapy is preferred by some experts [19]. As all
drugs are given twice a day, compliance is enhanced. The best results are with combina-
tions of a proton pump inhibitor, amoxicillin and clarithromycin or the combination of a
proton pump inhibitor with metronidazole and clarithromycin.
Ranitidine bismuth citrate triple therapy. Data from Europe and the United States
have shown high eradication rates with ranitidine bismuth citrate in combination with
amoxicillin and clarithromycin or metronidazole and clarithromycin. High eradication
rates have also been reported with acombination ofranitidine bismuth citrate and metron-
idazole and clarithromycin in Europe [20]. In the United States, an eradication rate of 95
percent was reported for the combination of ranitidine bismuth citrate with amoxicillin
and clarithromycin and 87 percent for ranitidine bismuth citrate with metronidazole and
tetracycline [21].
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PROBLEMS WITH THERAPY IN THE COMMUNITY
While controlled trials provide ameasure ofefficacy with a given regimen, the results
do not necessarily translate into routine clinical practice. The principal problems in rou-
tine practice are compliance and resistance [22, 23].
Compliance
Compliance with therapy is an important variable that affects results with all of the
treatment regimens. Compliance is a particular problem with bismuth-based triple thera-
py because of the number and frequency of the pills that need to be taken and the rela-
tively high incidence of minor side-effects. Decreased compliance is associated with a
decrease in eradication rates. A blister pack ofeach day's medication has been developed
forbismuth-based triple therapy, but it is considerably more expensive than the cost ofthe
drugs bought individually.
Resistance
Primary resistance to metronidazole is an important problem in some populations.
Resistance rates from 24 to 70 percent have been reported in the United States, and erad-
ication rates with metronidazole-containing regimens are decreased when resistance is
present [24]. A recent study found much higher prevalence rates of metronidazole resis-
tance (47 to 66percent) throughout the United States [25]. Clarithromycin resistance rates
have been increasing with time in the United States, from three to four percent in 1994 to
approximately 13 percent in 1996 [26]. Clarithromycin resistance is associated with a
decreased efficacy with clarithromycin containing regimens.
EFFECTIVENESS OF THERAPY IN ROUTINE CLINICAL PRACTICE
In a community-based study of gastroenterologists, Fennerty et al. [27] showed that
the combination ofmetronidazole, omeprazole and clarithromycin had an eradication rate
of92 percent, while omeprazole and clarithromycin dual drug therapy had an eradication
rate of76 percent, and bismuth based triple therapy had an eradication rate of73 percent.
Data on eradication rates in the community with primary care providers providing thera-
py are still lacking. A recent study suggests that only 39 percent of patients with peptic
ulcerdisease weretestedforH.pylori, and ofthese, only halfreceived treatment with anti-
microbials [28].
COST-EFFECTIVENESS MODELS OF DIFFERENT REGIMENS
Computer models that estimate the cost oftherapy with several ofthe regimens have
been developed. Vakil et al. compared four treatment regimens for the eradication of H.
pylori and demonstrated that a strategy to eradicate H.pylori was considerably less expen-
sive than traditional H2 receptor antagonist therapy even if the cost of the H2 receptor
antagonist was decreased to $1 for the entire year ofmaintenance oftherapy [29]. This is
because the principal determinant ofcost with H. pylori eradication therapy is the cost of
recurrence. Regimens with high eradication rates are cost-effective regardless of the ini-
tial cost ofthe drug therapy [18]. This model is relevant to the managed care environment
because costs were assessed over a two-year time frame. In another model based on actu-
al eradication results in a community-based trial (effectiveness data), we found that the
expected costs with proton pump inhibitor based triple therapy were lower than with two
drug therapies [30]. The new shorttriple drug therapies shouldreplace dual drug therapies
as the treatment ofchoice for H. pylori infection.
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In summary, despite significant advances in our understanding of the pathogenesis
and treatment of H. pylori related infection, treatment of patients in the community is
incomplete and inadequate.
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